This company listing is no longer active
Vertical Peak Holdings Past Earnings Performance
Past criteria checks 0/6
Vertical Peak Holdings has been growing earnings at an average annual rate of 2.9%, while the Pharmaceuticals industry saw earnings growing at 6% annually. Revenues have been declining at an average rate of 24.3% per year.
Key information
2.9%
Earnings growth rate
34.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -24.3% |
Return on equity | n/a |
Net Margin | -180.3% |
Last Earnings Update | 30 Apr 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Vertical Peak Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Apr 23 | 8 | -15 | 9 | 0 |
31 Jan 23 | 7 | -19 | 8 | 0 |
31 Oct 22 | 7 | -19 | 10 | 0 |
31 Jul 22 | 6 | -19 | 9 | 0 |
30 Apr 22 | 5 | 1 | 7 | 0 |
31 Jan 22 | 3 | -1 | 7 | 0 |
31 Oct 21 | 1 | -12 | 5 | 0 |
31 Jul 21 | 0 | -12 | 5 | 0 |
30 Apr 21 | -11 | -22 | -1 | 0 |
31 Jan 21 | -10 | -17 | -1 | 0 |
31 Oct 20 | -7 | -9 | 3 | 0 |
31 Jul 20 | 0 | -11 | 6 | 0 |
30 Apr 20 | 17 | -23 | 16 | 0 |
31 Jan 20 | 22 | -30 | 19 | 0 |
31 Oct 19 | 25 | -32 | 20 | 0 |
31 Jul 19 | 24 | -28 | 20 | 0 |
30 Apr 19 | 21 | -19 | 17 | 0 |
31 Jan 19 | 18 | -12 | 14 | 0 |
31 Oct 18 | 11 | -7 | 9 | 0 |
31 Jul 18 | 6 | -10 | 6 | 0 |
30 Apr 18 | 3 | -9 | 4 | 0 |
31 Jan 18 | 0 | -8 | 4 | 0 |
31 Oct 17 | 1 | -7 | 3 | 0 |
31 Jul 17 | 1 | -5 | 4 | 0 |
30 Apr 17 | 1 | -3 | 3 | 0 |
31 Jan 17 | 1 | -2 | 2 | 0 |
31 Oct 16 | 1 | -2 | 2 | 0 |
31 Jul 16 | 1 | -2 | 2 | 0 |
30 Apr 16 | 1 | -2 | 2 | 0 |
31 Jan 16 | 0 | -2 | 2 | 0 |
31 Oct 15 | 0 | -2 | 2 | 0 |
31 Jul 15 | 0 | -2 | 2 | 0 |
31 Jul 14 | 0 | -3 | 1 | 0 |
Quality Earnings: SPLI.F is currently unprofitable.
Growing Profit Margin: SPLI.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPLI.F is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare SPLI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPLI.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.9%).
Return on Equity
High ROE: SPLI.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.